RSP Systems
- Company typePrivate
- Founded2006
- HeadquartersOdense, Denmark
- Headcount11–50
- GTM typeB2B and B2C
- OfferingHardware or Manufacturing
RSP Systems firmographics
Firmographics- Name
- RSP Systems
- Legal name
- RSP Systems A/S
- Website
- https://rspsystems.com
- Company type
- Private
- Founded year
- 2006
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
RSP Systems industry classification
Industry- Product category
- Non-Invasive Glucose Monitoring
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Continuous Glucose Monitoring (CGM) Systems (HLAHAHAA)
- akta.pro secondary industries
- Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers) (HLAHACAL), Blood Glucose Monitoring (BGM) Meters & Test Strips (HLAHAHAG), Blood Glucose Monitoring Devices (Consumer CGM & Smart Glucometers) (CRACAQAE)
Keywords
Where RSP Systems is headquartered
LocationHeadquarters
- HQ city
- Odense
- HQ country
- Denmark
- HQ region
- Europe
Offices2 records
Markets served
RSP Systems business model
Business model- GTM type
- B2B and B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Revenue model
- Non-invasive Glucose Monitoring Devices: Future revenue stream from sales of the GlucoBeam Smart non-invasive glucose monitoring device. The device is currently investigational and not yet approved for commercial use. Revenue model likely to include device sales combined with subscription-based software/algorithm updates.
- Technology Licensing and Partnership: Potential revenue from licensing proprietary Raman spectroscopy technology, algorithms, and calibration methods to other medical device manufacturers. Company offers consulting services for companies seeking to develop non-invasive solutions.
- Algorithm and Software Services: Revenue from algorithm development and software deployment services as part of their non-invasive solutions offering. Phase 2-4 services include data model design, clinical trials, algorithm development, software design and deployment, and ongoing updates.
Go-to-market motion3 records
Distribution channels3 records
Marketing channels5 records
RSP Systems product offering
Product offeringCore offering
RSP Systems develops and is commercializing the GlucoBeam Smart device, a non-invasive glucose monitor that uses Critical-depth Raman spectroscopy and proprietary multivariate regression algorithms to measure blood glucose levels painlessly from the interstitial fluid in the upper living layers of the skin, eliminating the need for finger pricks or implanted sensors. The company also offers a Non-Invasive Solutions Service providing concept development, device configuration, data model design, clinical trials, algorithm development, and software deployment to other organizations seeking to leverage Raman spectroscopy technology for additional analytes and form factors.
Product overview
RSP Systems offers a unified portfolio centered on the GlucoBeam Smart device — a non-invasive glucose monitoring product using proprietary Raman spectroscopy technology. The company also provides contract development services (Non-Invasive Solutions Service) for other organizations seeking to leverage RSP's spectroscopic platform for additional analytes and form factors. The technology is built on supervised machine learning algorithms trained with real-world data spanning clinical studies and home-use settings.
Differentiator
Problem solved
Functional benefit
Brands
- GlucoBeam Smart: Non-invasive glucose monitoring device using Raman spectroscopy technology for pain-free blood glucose measurement
Products and services
- GlucoBeam Smart A non-invasive glucose monitoring device that uses Critical-depth Raman spectroscopy and proprietary multivariate regression algorithms to measure blood glucose levels painlessly from the upper living layers of the skin without needles or finger pricks. The device is intended for people with Type 1 and Type 2 diabetes and the pre-diabetes population who require regular glucose monitoring. GlucoBeam Smart is investigational and not yet approved for commercial use.
- Non-Invasive Solutions Service A four-phase advisory and contract development service for medical device manufacturers and healthcare technology companies wanting to develop non-invasive monitoring devices using Raman spectroscopy technology. Services cover concept development, device configuration, data model design, clinical trials, algorithm development, software design, and deployment support. Target customers are companies seeking to leverage RSP's spectroscopic platform for additional analytes and form factors.
Quantifiable outcome
- 99.8% of measurements within A+B zones in consensus error grid (Type 2 diabetes subset, 15+ day home use study)
- +4 more outcomes
Companies that use RSP Systems
Customer profileSegments3 records
Ideal customer profiles3 records
RSP Systems technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature5 records
RSP Systems partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and minor.
- Institute for Diabetes Technology, University of Ulm, GermanycoreCollaborated on Nature Scientific Reports publication (March 2025) covering pre-trained calibration models for non-invasive glucose monitoring. RSP Systems collaborated with Dr. Guido Freckmann and Eva Zschornack from the Institute, along with clinical advisor Professor K.D. Hepp.
- Steno Diabetes Center CopenhagencoreClinical study site for multiple RSP studies including RSP-17 (hypoglycemia range assessment) and RSP-24 (long-term calibration stability). Steno Diabetes Center is a leading Danish diabetes research and treatment center.
- Steno Diabetes Center OdensecoreClinical study site for RSP-10 (long-term calibration stability) and RSP-24 studies. Located at Odense University Hospital where RSP Systems conducted early feasibility studies.
- Steno Diabetes Center AarhuscoreClinical study site for RSP-19 study evaluating laser polarization impact on device performance.
- Sahlgrenska University Hospital, SwedencoreClinical study site for RSP-08 study comparing multiple validated glucose reference methods including microdialysis, capillary, and CGM systems.
- m&i-Fachklinik Bad Heilbrunn, GermanyminorSite 1 for Glucobrunn study (RSP-09) conducted with 30 participants with Type 1 and Type 2 diabetes for calibration model establishment.
Scale indicators6 records
Recent moves6 records
Expansion highlights6 records
RSP Systems competitors and assessment
Company assessmentBroad incumbents
- LifeScan (OneTouch): OneTouch blood glucose monitoring brand owned by Platinum Equity. Comparable incumbent in the BGM space whose customers RSP could address with non-invasive alternatives.
- Ascensia Diabetes Care: Manufacturer of CONTOUR blood glucose meters. Relevant incumbent peer in the diabetes monitoring space, particularly for the pre-diabetes and consumer health segments RSP targets.
- Roche Diabetes Care: Major diabetes care company with Accu-Chek blood glucose monitoring portfolio. Comparable as a large incumbent RSP would compete with or seek licensing partnership from.
- Abbott Diabetes Care: Manufacturer of the FreeStyle Libre line of flash and continuous glucose monitors, the world's largest CGM by volume. Highly relevant as the dominant non-invasive-adjacent incumbent whose market RSP would target or partner with.
- Dexcom: Market leader in continuous glucose monitoring with the G6 and G7 CGM systems, dominant in the U.S. and globally. Directly comparable as the incumbent RSP would either replace or partner with in the glucose monitoring space.
- Medtronic Diabetes: Operates the Guardian CGM system integrated with insulin pumps (MiniMed). Comparable as a major incumbent in diabetes monitoring and a potential strategic acquirer of RSP's non-invasive technology.
Emerging players
- NovioSense: Dutch company developing a tear-fluid-based continuous glucose sensor. Comparable as a European emerging glucose monitoring innovator using novel biomarker approaches.
Direct peers
- Senseonics Holdings: Developer of Eversense, an implantable long-term CGM. Closely comparable as a pre-commercial-to-commercial stage glucose monitoring company competing on durability and patient experience, both seeking differentiation from standard CGMs.
- DiaMonTech: Berlin-based company developing non-invasive glucose monitoring using infrared spectroscopy/photothermal technology. Closely comparable as a European peer pursuing non-invasive glucose via optical/photonic methods.
- Integrity Applications (GlucoTrack): Developer of GlucoTrack, a non-invasive glucose monitoring device using a combination of ultrasonic, electromagnetic, and thermal technologies. Direct peer in the non-invasive glucose device category.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
RSP Systems social profiles
Digital presenceRSP Systems compliance and trust
Trust signalCompliance4 records
RSP Systems financial estimates
Financial estimateRevenue estimate
Valuation estimate
RSP Systems leadership team
Management profileNumber of profiles
Profiles8 records
RSP Systems funding detail
Funding detailFunding overview
Funding rounds9 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
RSP Systems M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about RSP Systems
What does RSP Systems do?
RSP Systems develops and is commercializing the GlucoBeam Smart device, a non-invasive glucose monitor that uses Critical-depth Raman spectroscopy and proprietary multivariate regression algorithms to measure blood glucose levels painlessly from the interstitial fluid in the upper living layers of the skin, eliminating the need for finger pricks or implanted sensors. The company also offers a Non-Invasive Solutions Service providing concept development, device configuration, data model design, clinical trials, algorithm development, and software deployment to other organizations seeking to leverage Raman spectroscopy technology for additional analytes and form factors.
Is RSP Systems a public or private company?
RSP Systems is a private company. It is classified as venture growth investor backed and is currently operating.
When was RSP Systems founded?
RSP Systems was founded in 2006. It employs 11 to 50 people.
Where is RSP Systems based?
RSP Systems is headquartered in Odense, Denmark, in the Europe region.
How does RSP Systems make money?
Three revenue lines are on record. Non-invasive Glucose Monitoring Devices are the primary driver. The others are technology Licensing and Partnership and algorithm and Software Services.
Who are RSP Systems's main competitors?
Broad incumbents on record are LifeScan (OneTouch), Ascensia Diabetes Care, Roche Diabetes Care, Abbott Diabetes Care, Dexcom and Medtronic Diabetes. NovioSense is listed as an emerging player. Direct peers are Senseonics Holdings, DiaMonTech and Integrity Applications (GlucoTrack).
Does RSP Systems have an API?
No public API is recorded for RSP Systems.
What industry is RSP Systems in?
RSP Systems's product category is Non-Invasive Glucose Monitoring. Its primary akta.pro industry code is HLAHAHAA, Continuous Glucose Monitoring (CGM) Systems, with a secondary code of HLAHACAL, Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers). Its NAICS code is 334510 and its SIC code is 3845.